#United States #New York #Class Action #Levi & Korsinsky #Unicycive

Unicycive Therapeutics Class Action Overview

Levi & Korsinsky, LLP has recently announced a class action lawsuit on behalf of investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This comes after the company faced substantial declines in stock value following the FDA’s issuance of a second Complete Response Letter (CRL) regarding their New Drug Application for oxylanthanum carbonate (OLC). The lawsuit alleges that Unicycive did not adequately audit or verify compliance at the manufacturing facility used for their product, which led to a serious compliance verification gap that ultimately hurt shareholders.

Key Allegations in the Lawsuit

The class action claims that the management of Unicycive Therapeutics did not conduct proper inspections or ensure that their third-party manufacturing vendor adhered to current Good Manufacturing Practices (cGMP). This lack of verification is centered around the failure to ensure that previously identified deficiencies were adequately addressed, which was a pivotal point raised by the FDA in both Complete Response Letters.

The lawsuit expresses that Unicycive inaccurately portrayed its position in the market by suggesting that progress had been made regarding FDA compliance, when in fact, no inspection had taken place prior to resubmission of the NDA in December 2025. The consequences of these actions resulted in a staggering 39.1% drop, equating to a $3.01 loss per share, within a single trading session after the second CRL announcement on June 30, 2026.

Timeline of Events

• - December 29, 2025: Investors who purchased UNCY shares within this date became eligible for the class action suit.
• - June 30, 2026: FDA issues a second CRL based on the same manufacturing deficiencies as the first one, leading to significant financial losses for investors.
• - November 2, 2026: Deadline for investors to file applications to serve as lead plaintiff, giving them oversight of the class action case.

Legal Insights

Joseph E. Levi, a renowned attorney at Levi & Korsinsky, commented on the implications of the lawsuit, stating, "This case presents important questions about manufacturing compliance disclosure obligations in the biotechnology sector, where a single contract vendor can determine whether an approval proceeds. Investors had been led to believe that the resubmission reflected verified progress that was not independently confirmed by the company."

The lawsuit also points out that Unicycive acknowledged risks linked to the potential for a repeat inspection failure, which could delay the regulatory approval process significantly—by an estimated 6 to 12 months. This form of undisclosed risk is a central component of the securities fraud claims presented within the class action.

What Should Investors Do?

Investors who experienced financial losses from Unicycive Therapeutics stock should gather records documenting their share purchases to assess their eligibility for potential recovery. Conducting a no-cost evaluation with Levi & Korsinsky can aid investors in understanding their involvement in the class action without immediate action necessary to maintain eligibility as a class member.

Conclusion

The lawsuit against Unicycive Therapeutics highlights critical compliance issues within the biotech sector and the importance of transparent communication with investors. For those affected, the potential for recovery signifies a key opportunity to address financial losses resulting from this circumstance. Contacting Levi & Korsinsky or submitting your claim could be the first step towards achieving justice.

For direct inquiries, contact:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Phone: (212) 363-7500